Global, regional, and national burdens of heart failure in adolescents and young adults aged 10–24 years from 1990 to 2021: an analysis of data from the Global Burden of Disease Study 2021

• Published in: EClinicalMedicine 2025-01, Vol.79, Article 102998
• Main Authors: Yang, Chengzhi, Jia, Yuhe, Zhang, Changlin, Jin, Zening, Ma, Yue, Bi, Xuanye, Tian, Aiju
• Format: Article
• Language: English
• Subjects: Adolescents; Heart failure; Prevalence; Years lived with disability; Young adults
• ISSN: 2589-5370; 2589-5370
• DOI: 10.1016/j.eclinm.2024.102998

Prior studies suggest prevalence of heart failure (HF) has remained steady or progressively decreased over past 30 years in the general population. Whether this favourable trend occurred in adolescents and young adults aged 10–24 years has yet to be elucidated. We aim to identify the trends in the burden of HF in this young population from 1990 to 2021 to inform areas for targeted intervention and prevention efforts. We analyzed data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. The case number and rates per 100,000 population of prevalence and years lived with disability (YLDs) of HF at the global, regional, and national level in the population aged 10–24 years from 1990 to 2021 were reported. In addition, the HF trends by age, sex, and socio-demographic index (SDI) were analyzed. Furthermore, we calculated the average annual percentage changes (AAPC) and identified the year with the most pronounced changes in the trends with the joinpoint regression analysis. In detail, we divided the study population into three age groups: 10–14 years old, 15–19 years old, and 20–24 years old. We also employed the Bayesian age-period-cohort models (BAPC) to predict the future burden of HF up to 2030. Globally, the prevalence and YLDs rates of HF among adolescents and young adults in 2021 were 148.1 (95% uncertainty interval [UI]: 118.8–185.7) and 14.4 (9.2–21.2) per 100 000 population, increased from 125.5 (100.0–157.7) and 12.2 (7.8–17.8) in 1990 respectively. Noticeable changes in HF prevalence were found in 1994, 2001, 2004, 2010, and 2018. Regionally, East Asia had the most pronounced increase in HF prevalence rate (AAPC = 1.35 [1.28–1.43]) and YLDs rate (AAPC = 1.32 [1.27–1.38]), while the highest HF prevalence rates per 100,000 population were observed in High-income North America (232 [185.4–292]). The prevalence and YLDs of HF increased in most countries except Australia, Canada, and Spain. The largest increase in HF prevalence rate was observed in China (AAPC = 1.39 [1.31–1.48]). By SDI quintile, the middle-SDI quintile countries had the largest increase in prevalence and YLDs rates. By sex, males had a higher prevalence rate per 100,000 population than females (158.0 [95% UI: 126.7–198.9] vs 137.6 [95% UI: 110.0–172.2]) in 2021. Among three age groups, the largest increase in HF prevalence from 1990 to 2021 was found in individuals aged 20–24 years (AAPC = 0.61 [0.6–0.61]). Among all causes of HF, cardiomyopathy and myocardit